Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07530172 · ClinicalTrials.gov registry record · Phase 2
Radioembolization Versus External Radiation Therapy
A Phase 2 study, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT07530172 is a Phase 2 study that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 146 participants.
The verdict
NCT07530172, a Phase 2 study, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
The proposed study is a single site, prospective, randomized phase 2 study to evaluate the efficacy and tolerability transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma. The SBRT arm of the trial will involve standard SBRT delivered over 3-5 fractions as tolerated with dose/total therapy adjusted as needed for safety. The TARE arm of the trial will involve a planning arteriogram followed by selective transarterial delivery of Yttrium-90 into the segmental (≤2) artery supplying the tumor. Administered activity will be an amount prescribed to deliver a dose ≥200 Gy to the perfused tissue. The primary endpoint is the rate of re-treatment of the index lesion over 12 months.
Interventions
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
- RADIATION Transarterial Radioembolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07530172
The ClinicalTrials.gov registry entry for NCT07530172 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT07530172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07530172 about?
NCT07530172 is a clinical study titled "Radioembolization Versus External Radiation Therapy". The proposed study is a single site, prospective, randomized phase 2 study to evaluate the efficacy and tolerability transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma. The SBRT arm of the trial will involve standard SBRT delivered o...
What is the current status of trial NCT07530172?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2025-12-08. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT07530172?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (RADIATION), Transarterial Radioembolization (RADIATION).
Who is sponsoring clinical trial NCT07530172?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.